Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
silodosin + ningmitai
- Development stage
- Unknown
- Lead developer
- Xintian Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Silodosin + Ningmitai is a combination therapy consisting of silodosin, a selective alpha-1 adrenergic receptor antagonist, and Ningmitai, an herbal medicine formulation. This combination is being studied for the treatment of benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS). Silodosin works by selectively blocking alpha-1A adrenergic receptors in the prostate and bladder neck, leading to relaxation of smooth muscle and improved urine flow. Ningmitai capsules are a traditional Chinese medicine used for urological conditions such as prostatitis and urinary tract infections; their mechanism involves anti-inflammatory effects but specific molecular targets are not well defined. The combination aims to provide symptomatic relief in BPH by leveraging both pharmacological smooth muscle relaxation (silodosin) and potential anti-inflammatory or adjunctive effects from the herbal components of Ningmitai[1][4][6].
- Brand names
- Qianweitai + Ningmitai
- Other names
- silodosin and ningmitaisilodosin combined with ningmitaiSilodosin Capsules plus Ningmitai Capsules
02
Targets
ADRA1A (α1A)
Beyond the preview
Go deeper on silodosin + ningmitai.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on silodosin + ningmitai.